Category - Developments

Developments

HCW ups Calithera to buy on steady progress of clinical programs

H.C. Wainwright upgraded Calithera Biosciences (NASDAQ:CALA) to “buy” from “neutral” with a 12-month price target of $8, citing two ongoing clinical development programs that are expected to provide data updates in the...

August 29, 2022

Developments

First patient dosed in MindMed GAD study with LSD

MindMed (NASDAQ:MNMD; NEO:MMED) announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of generalized...

August 29, 2022

Developments

First patient dosed in Annovis Bio Phase 3 trial in early PD

The first patient has been dosed in Annovis Bio’s (NYSE:ANVS) Phase 3 clinical trial evaluating its buntanetap in early Parkinson’s disease (PD). The Phase 3 trial will enroll 450 early PD patients to be treated...

August 24, 2022

Developments

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVAIL study of TNX-102 SL as a potential treatment for a subset of patients with Long COVID syndrome whose symptoms overlap with...

August 22, 2022

Developments

FDA slaps clinical hold on Pharvaris trials of PHA121 in U.S.

The FDA verbally informed Pharvaris (NASDAQ:PHVS) that, based on its review of nonclinical data, it is placing a clinical hold on clinical trials of PHA121 in the U.S. under two Pharvaris IND applications for the...

August 22, 2022

Developments

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With what we believe to be a...

August 17, 2022

Developments

Blue Water to explore development of VLP monkeypox vaccine

Blue Water Vaccines (NASDAQ:BWV) plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle (VLP) platform. The company’s shell and protrusion...

August 17, 2022

Developments

First patients treated with LENSAR’s ALLY cataract treatment

The first commercial cases of the LENSAR (NASDAQ:LNSR) ALLY Adaptive Cataract Treatment System were performed by Robert Weinstock, M.D. at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted...

August 16, 2022

Developments

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human...

August 11, 2022

Developments

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

SAB Biotherapeutics (NASDAQ:SABS) will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019...

August 10, 2022

Category - Developments

Subscribe